To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
The metastatic potential of pediatric solid tumors to the bone marrow varies. This chapter reviews the indications of bone marrow evaluation in children with solid tumors. The various morphologic and immunohistochemistry patterns of neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and other tumors are presented and well-illustrated. The bone marrow requirements for adequacy and reporting are addressed as well. The chapter also provides helpful information on how to distinguish non-hematopoietic tumor cells from the normal B-cell progenitors, a frequent finding in patients with solid tumors regardless of the metastatic state.
Chemotherapy suppresses the proliferation and induces brisk cell death not only of the neoplastic cells but also to the rapidly dividing hematopoietic cells in the marrow. This chapter explores the characteristic short- and long-term morphologic changes and bone marrow recovery of children and young adults who underwent chemotherapy for hematologic and non-hematologic neoplasms. It also discusses the changes in the peripheral blood and the marrow of children and young adults receiving growth factor therapy, hematopoietic stem cell transplant, and chimeric antigen receptor T-cell therapy. It provides helpful information on bone marrow reporting after such therapy.
This chapter covers initial diagnosis of B-lymphoblastic leukemia (B-ALL), and measurable disease detection (MRD) post therapy by flow cytometry. The classic and variant immunophenotypic features of B-ALL are illustrated, correlated with molecular genetic characteristics, and summarized in a genotype-phenotype table. The key features are provided in the differential diagnosis of B-ALL with aberrant MPO versus mixed B/myeloid acute leukemia (MPAL), as well as B-ALL with a mature phenotype versus high grade B cell lymphoma. Under B-ALL MRD detection, the common immunophenotypic alterations are demonstrated by comparing them to normal immature B cells (hematogones). Strategies for MRD detection post targeted therapy are also discussed. The pros and cons of flow cytometry MRD are compared with molecular MRD, including NGS sequencing (Clonoseq) and BCR::ABL1 quantitative PCR. The challenges, including loss of lineage markers, lineage switch, and normal mimics, are discussed and illustrated under diagnostic pitfalls.
This chapter discusses the immunophenotypic features of adult and pediatric follicular lymphoma (FL), including those with atypical immunophenotypes such as CD5+ or CD10−. The differential diagnosis includes CD10+ non-neoplastic but monotypic B-cell processes and CD10+ B-cell lymphomas/leukemias other than FL.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.